Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been
intensely investigated for clinical applications within the last decades. However, the majority …

Tremendous progress has been achieved in the field of tissue engineering in the past
decade. Several major challenges laid down 10 years ago, have been studied, including …

Mesenchymal stromal cells (MSCs) for basic research and clinical applications are
manufactured and developed as unique cell products by many different manufacturers and …

Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely,
peptides demonstrate higher efficiency in tissue penetration and cell internalization than …

Mesenchymal stromal cells (MSCs) are currently being investigated for use in a wide variety
of clinical applications. For most of these applications, systemic delivery of the cells is …

Mesenchymal stem cells (MSCs) are promising candidates for adult cell therapies in
regenerative medicine. To fully exert their potential, efficient homing and migration toward …

The worldwide incidence of bone disorders and conditions has trended steeply upward and
is expected to double by 2020, especially in populations where aging is coupled with …

The development of mesenchymal stem cells (MSCs) as cell-based drug delivery vectors for
numerous clinical indications, including cancer, has significant promise. However, a …

Tissue engineering of bone and cartilage has progressed from simple to sophisticated
materials with defined porosity, surface features, and the ability to deliver biological factors …

The broad repertoire of secreted trophic and immunomodulatory cytokines produced by
mesenchymal stem cells (MSCs), generally referred to as the MSC secretome, has …